Friday
09.25.2020
3:17 AM
Login form
Search
Calendar
Entries archive

My site

Main » 2019 » November » 13

 Aims To Boost Teamwork Efficiency and Interactive Collaboration for businesses and education industry

 

DUBAI, United Arab Emirates-Tuesday 12 November 2019 [ AETOS Wire ]

BenQ, the global leader in Display Solutions, showcased a new series of display products including a Smart Projector and DuoBoard Interactive Flat Panel at “More Than Connection”. The launch event was hosted in Dubai, inviting its partners across the Middle East & Turkey. The event was also honoured by a key guest speaker from GEMS Education, Mr. Shabeer Mohammed, Vice President and Group Head of Technology Services, who touch based on the Evolution of Classroom Technology and Vision of Future Classrooms.

The new range of display products aim to meet multiple needs of workstyle reform for better teamwork efficiency, collaboration and productivity. One of the key highlights of the event was BenQ’s Education Display solutions for smart campuses. The ne ... Read more »

Views: 23 | Added by: africa-live | Date: 11.13.2019

Deployment to enable next-generation transformation of customer self-service

EAST BRUNSWICK, New Jersey & BANGALORE, India-Tuesday 12 November 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced the successful implementation of SAP S/4HANA® software for Sydney Water, a statutory state-owned corporation wholly owned by the New South Wales Government. Wipro has also integrated modules of Industry-Specific Solution for the Utilities Industry (IS-U), Customer Relationship Management (CRM) and Flexible Real Estate Management (RE-FX) globally for the customer.

Leveraging SAP S/4HANA, Sydney Water will be able to deploy state-of-the-art features in its billing and customer services, enabling simplified billing processes and next-generation transformation of customer self-service.

Built with additional capab ... Read more »

Views: 24 | Added by: africa-live | Date: 11.13.2019 | Comments (0)

EMPULSE is a superiority study that will assess the clinical benefit, safety and tolerability of 10 mg daily empagliflozin in acute heart failure1


INGELHEIM, Germany & INDIANAPOLIS, US-Tuesday 12 November 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the initiation of EMPULSE, the sixth Phase III study in the empagliflozin heart failure programme. The study will assess whether in-hospital administration of empagliflozin 10 mg daily improves heart failure outcomes when initiated in people hospitalised for any type of acute heart failure event once they have been stabilised. The study will include participants both with and without type 2 diabetes.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191112005650/en/

Heart failure is the leading cause of hospitalisation in Europe and the US, and half of people with heart ... Read more »

Views: 22 | Added by: africa-live | Date: 11.13.2019

ISTANBUL-Tuesday 12 November 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- P.I. Works is recently awarded by Turkcell to deploy its advanced Geolocation solution to transform customer experience and drive network efficiency. P.I. Works solution provides capabilities that will help Turkcell visualize customer experience with higher accuracy and turn these insights into customer-centric actions. The solution significantly reduces drive test efforts; thus leading to lower carbon footprint while saving time, energy and costs for Turkcell.

With this new agreement, P.I. Works Geolocation solution will be deployed to provide measurable insights about customer experience by correlating data from multiple sources. As the solution will be running on the same platform with P.I. Works Centralized SON, the customer insights collected by the Geolocation solution can be used by the Centralized SON to take more targeted network enhancement actions. Additionally, P.I. Works solution will be ... Read more »

Views: 17 | Added by: africa-live | Date: 11.13.2019 | Comments (0)

Company's integrated application management and award-winning support services provide Oracle licensees with unique solution that simplifies IT operations, frees up resources to focus on innovation and achieves better business outcomes

LAS VEGAS-Saturday 9 November 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced the global availability of its Application Management Services (AMS) for Oracle, which includes coverage for Oracle Database, Middleware and a wide range of Oracle applications including E-Business Suite, JD Edwards, PeopleSoft and Siebel.

In addition to leveraging Rimini Street’s award-winning Support Services for Oracle that replaces expensive and less robust software vendor annual support with a more responsive and comprehensive sup ... Read more »

Views: 23 | Added by: africa-live | Date: 11.13.2019 | Comments (0)

- Results Demonstrated Statistically Significant Improvement in Progression-Free Survival -

- Data to be Submitted for Presentation at an Upcoming Medical Meeting -

CAMBRIDGE, Mass. & OSAKA, Japan-Sunday 10 November 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) ("Takeda") today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The trial evaluated the effect of single-agent oral NINLARO™ (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation. TOURMALINE-MM4 is the first industry sponsored Phase 3 trial to explore the concept of “switch” maintenance, the use of medicines not included in initial induction therapy, in this setting. NINLARO is currently not approved for this specific use.

“We are very en ... Read more »

Views: 30 | Added by: africa-live | Date: 11.13.2019 | Comments (0)